Literature DB >> 15283769

Cyclooxygenase-2 and the renal renin-angiotensin system.

R C Harris1, M-Z Zhang, H-F Cheng.   

Abstract

In the kidney, cyclooxygenase-2 (COX-2) is expressed in the macula densa/cTALH and medullary interstitial cells. The macula densa is involved in regulating afferent arteriolar tone and renin release by sensing alterations in luminal chloride via changes in the rate of Na(+)/K(+)/2Cl(-) cotransport, and administration of non-specific cyclooxygenase inhibitors will blunt increases in renin release mediated by macula densa sensing of decreases in luminal NaCl. High renin states [salt deficiency, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers, diuretic administration or experimental renovascular hypertension] are associated with increased macula densa/cTALH COX-2 expression. Furthermore, there is evidence that angiotensin II and/or aldosterone may inhibit COX-2 expression. In AT1 receptor knockout mice, COX-2 expression is increased similar to increases with ACE inhibitors or AT1 receptor blockers. Direct administration of angiotensin II inhibits macula densa COX-2 expression. Previous studies demonstrated that alterations in intraluminal chloride concentration are the signal for macula densa regulation of tubuloglomerular feedback and renin secretion, with high chloride stimulating tubuloglomerular feedback and low chloride stimulating renin release. When cultured cTALH or macula densa cells were incubated in media with selective substitution of chloride ions, COX-2 expression and prostaglandin production were significantly increased. A variety of studies have indicated a role for COX-2 in the macula densa mediation of renin release. In isolated perfused glomerular preparations, renin release induced by macula densa perfusion with a low chloride solution was inhibited by a COX-2 inhibitor but not a COX-1 inhibitor. In vivo studies in rats indicated that increased renin release in response to low-salt diet, ACE inhibitor, loop diuretics or aortic coarctation could be inhibited by administration of COX-2-selective inhibitors. In mice with genetic deletion of COX-2, ACE inhibitors or low-salt diet failed to increase renal renin expression, although renin significantly increased in wild type mice. In contrast, in COX-1 null mice there were no significant differences in either the basal or ACE inhibitor-stimulated level of renal renin activity from plasma or renal tissue compared with wild type mice. In summary, there is increasing evidence that COX-2 expression in the macula densa and surrounding cortical thick ascending limb cells is regulated by angiotensin II and is a modulator of renal renin production. These interactions of COX-2 derived prostaglandins and the renin-angiotensin system may underlie physiological and pathophysiological regulation of renal function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15283769     DOI: 10.1111/j.1365-201X.2004.01329.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  37 in total

1.  Assessing the application of tissue microarray technology to kidney research.

Authors:  Ming-Zhi Zhang; Yinghao Su; Bing Yao; Wei Zheng; Mark Decaestecker; Raymond C Harris
Journal:  J Histochem Cytochem       Date:  2010-01-19       Impact factor: 2.479

2.  Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.

Authors:  Huifang Cheng; Xiaofeng Fan; Gilbert W Moeckel; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2011-07       Impact factor: 10.121

3.  Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors.

Authors:  Ming-Zhi Zhang; Bing Yao; Hui-Fang Cheng; Su-Wan Wang; Tadashi Inagami; Raymond C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

4.  Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain.

Authors:  Pierre-Olivier Hétu; Denis Riendeau
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

Review 5.  Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs.

Authors:  Noritaka Kawada; Toshiki Moriyama; Harumi Kitamura; Ryohei Yamamoto; Yoshiyuki Furumatsu; Isao Matsui; Yoshitsugu Takabatake; Yasuyuki Nagasawa; Enyu Imai; Christopher S Wilcox; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

Review 6.  Hyperfiltration-associated biomechanical forces in glomerular injury and response: Potential role for eicosanoids.

Authors:  Mukut Sharma; Ram Sharma; Ellen T McCarthy; Virginia J Savin; Tarak Srivastava
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-01-17       Impact factor: 3.072

7.  Down-regulation of cyclooxygenase-2 by the carboxyl tail of the angiotensin II type 1 receptor.

Authors:  Rapita Sood; Waleed Minzel; Gilad Rimon; Sharon Tal; Liza Barki-Harrington
Journal:  J Biol Chem       Date:  2014-09-17       Impact factor: 5.157

Review 8.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 9.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

10.  Intrarenal dopaminergic system regulates renin expression.

Authors:  Ming-Zhi Zhang; Bing Yao; Xiaofeng Fang; Suwan Wang; James P Smith; Raymond C Harris
Journal:  Hypertension       Date:  2009-01-12       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.